

Dear Oonagh

Following a review of the response and additional data submitted by MSD on 28 January, the ERG have some requests for additional data and information listed below:

Priority

- 1) Please provide the 104 week radiographic, SF-36, HAQ and ACR data for the GO-BEFORE trial which are referred to on page 7 of the response
- 2) Please provide the 104 week radiographic, SF-36, HAQ and ACR data for the GO-FORWARD trial which are referred to on page 8 of the response

In addition, the ERG have requested some further information on the following, which would assist in their evaluation of the additional data submitted by MSD

- 3) For the DMARD-experienced and TNF-experienced models submitted, please provide a full list of all changes made (comparing to the original submitted models)
- 4) Please can you provide full details and results, including all outcome measures, from the phase II trial referred to on page 17 of the response
- 5) Please can you provide actual references to the particular trials/data sources referred to throughout the document (e.g. what tocilizumab trial was used?).

We would be grateful if you could provide these data and references by **Thursday 3 March**.

Kind regards

Sally

Sally Doss, PhD

Technical Analyst

Centre for Health Technology Evaluation

National Institute for Health and Clinical Excellence

